<DOC>
	<DOCNO>NCT03097796</DOCNO>
	<brief_summary>Subjects hematologic malignancy recipient first allogenic autologus hematopoietic stem cell transplant , without evidence respiratory infection , receive 4 dos PUL-042 solution inhalation 2 week period . Subject evaluated tolerability drug . If tolerate , dose escalation may occur 4 dose level test</brief_summary>
	<brief_title>A Multiple Ascending Dose Study PUL-042 Stem Cell Transplant Recipients</brief_title>
	<detailed_description>This open-label multiple ascend dose study 3+3 study design examine safety tolerability PUL-042 Inhalation Solution subject hematologic malignancy recipient first allogenic autologus hematopoietic stem cell transplant . Subjects receive 4 dos 2 week . Cohort size 3 subject , 3 subject complete treatment follow-up dose level , subject data evaluate independent data safety monitoring committee prior dose additional subject . The Committee may recommend increase dose , maintain dose , decrease dose . Once maximum dose determine , may 6 additional subject dose level .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>1 . Subjects hematologic malignancy recipient first allogeneic autologous hematopoietic stem cell transplantation presently clinically stable . 2 . Pulse oximetry hemoglobin saturation ≥92 % room air . 3 . Adult ( ≥18 year ) . 4 . Spirometry ( FEV1 force vital capacity [ FVC ] ) ≥80 % predict value . 5 . Diffusing capacity lung carbon monoxide ( DLco ) ≥80 % predict value . 6 . If female , must either postmenopausal ( one year great without menses ) , surgically sterile , , female subject childbearing potential capable conception must : practice two effective method birth control 7 . If female , must pregnant , plan become pregnant , nurse child study 30 day completion study . 8 . If male , must surgically sterile willing practice two effective method birth control 9 . Ability understand give inform consent . 1 . Subjects evidence respiratory infection include sign symptom either low respiratory infection ( LRI ) upper respiratory infection ( URI ) 2 . Known history chronic pulmonary disease 3 . Subjects treat fungal , viral , bacterial pneumonia 4 . Exposure investigational agent ( defined agent approve Food Drug Administration [ FDA ] ) within 30 day prior Screening Visit . 5 . Patients relapse and/or refractory underlie hematologic malignancy . 6 . HSCT recipients underwent ex vivo Tcell depletion graft , mismatch , cord haplo identical blood transplantation . 7 . HSCT recipient active and/or chronic graft versus host disease . 8 . Patients systemic corticosteroid ( oral intravenous ) 9 . Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mL . 10 . Clinically significant bacteremia fungemia 11 . Current smoker subject history smoking .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>